Burkitt Lymphoma Network

What Burkitt Lymphoma Network does

The Burkitt Lymphoma Network is a non-profit research consortium founded in December 2022 and headquartered in Amsterdam, the Netherlands, that coordinates global research on Burkitt Lymphoma (BL), a rare aggressive B-cell lymphoma. It serves adult hematologists, pediatricians, and basic researchers across 20+ countries and 80+ specialist members, organized into four Working Groups: Basic BL Research, Paediatric BL, Population-Based Research/Registries, and Clinical Trials. The network engages members through in-person meetings at major hematology conferences (ASH, EHA, ICML), virtual working group sessions, and a WordPress-hosted publication and trial-information website.

Its core products are research-coordination assets rather than commercial software. The principal product is the Burkitt Lymphoma Registry (BLR), a prospective observational international registry of newly diagnosed BL patients that collects clinical data and tumor samples via a RedCap database built by Associazione Angela Serra for Cancer Research (Modena, Italy). The BLR protocol received Medical Ethical Committee approval from Amsterdam UMC in October 2024, with Amsterdam UMC serving as the coordinating center under Dr. Dorith Claushuis. Additional offerings include the CARTD-BG-01 Phase I trial (ARI0003 CART19/BCMA cells for relapsed/refractory B-cell aggressive lymphomas, conducted at Hospital Clinic de Barcelona), an EBV vaccine research project for children with BL, and a translational project characterizing sporadic BL in central Africa.

The business model is non-commercial: revenue is derived from donations and research grants rather than fees, memberships, or licensing. The network does not charge for participation in trials, the registry, or working groups, and no pricing structure or commercial product exists. Strategic partnerships — with Amsterdam UMC (registry coordination), Associazione Angela Serra (database infrastructure), AI-REAL (Africa-focused research funding), and Hospital Clinic de Barcelona (cellular therapy trials) — underpin operations. Governance is by a Board of Directors chaired by Martine Chamuleau with board members Ann LaCasce and Adam Olszweski.

Name

Burkitt Lymphoma Network

Legal name

International Burkitt Lymphoma Network

Website

https://burkitt-lymphoma.org

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

The Burkitt Lymphoma Network is a Netherlands-based non-profit research consortium founded in 2022 that coordinates global clinical trials, registries, and translational research on Burkitt Lymphoma for 80+ adult hematologists, pediatricians, and basic researchers across 20+ countries.

Ownership category

akta.pro rank

Product category

Medical Research Network

SIC

Services-Membership Organizations (8600), Services-Health Services (8000)

akta.pro primary industry

Rare Disease & Special Needs Support Organizations (BPAGACAM)

akta.pro secondary industries

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Disease Registries (Cancer, Immunization, Rare Disease, etc.) (HLAJAJAE)

Keywords

• Lymphoma research network
• Clinical trials coordination
• Cancer registry services
• Hematology research collaboration
• Medical research consortium

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Donations and Grants: As a non-profit organization, the Burkitt Lymphoma Network operates through donations and research grants. The network received a donation for Burkitt Lymphoma Research in Africa from Professor Dr Anna Schuh and Dr Clara Chamba (AI-REAL). Revenue is not generated through commercial products or services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

The Burkitt Lymphoma Network is a non-profit global research consortium that coordinates clinical trials, maintains an international patient registry, and supports research projects focused on Burkitt Lymphoma. It connects adult hematologists, pediatricians, and basic researchers across 20+ countries through four working groups (Basic Research, Pediatric, Population-Based Research/Registries, and Clinical Trials), with Amsterdam UMC serving as the coordinating center for the prospective Burkitt Lymphoma Registry.

Product overview

Burkitt Lymphoma Network is a non-profit organization operating as a global research coordination platform rather than a traditional software product company. The network's core offerings include the Burkitt Lymphoma Registry (BLR), a prospective international patient registry using REDCap database for clinical data and tumor sample collection; interventional and observational clinical trials such as CARTD-BG-01; and supported research projects including EBV vaccine research and sporadic Burkitt Lymphoma studies. The network organizes its activities through four Working Groups: Basic Burkitt Lymphoma Research, Paediatric Burkitt Lymphoma, Population Based Research/Registries, and Clinical Trials. The organization facilitates collaboration among adult hematologists, pediatricians, and researchers across multiple countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Burkitt Lymphoma Registry (BLR) A prospective observational international registry of patients with newly diagnosed Burkitt Lymphoma. The registry collects clinical data and tumor samples from patients worldwide to obtain accurate information on epidemiology, pathology, and outcomes (2-year progression free survival). Built on REDCap by Associazione Angela Serra for Cancer Research, with Amsterdam UMC serving as coordinating center.
• CARTD-BG-01 Clinical Trial A phase I pilot trial evaluating the safety and efficacy of ARI0003 (CART19/BCMA cells) in patients with relapsed/refractory B-cell aggressive lymphomas, including Burkitt Lymphoma. Conducted at Hospital Clinic de Barcelona, Spain.
• EBV Vaccine Research Project

Quantifiable outcome

• Prospective BLR protocol approved by Medical Ethical Committee of Amsterdam UMC in October 2024
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Partnerships

Four partnerships are on record, tiered core and major.

• Amsterdam UMCcoreStrategic or Co-development Partner · 1 October 2024Amsterdam UMC serves as the coordinating center for the Burkitt Lymphoma Registry (BLR). The Medical Ethical Committee of Amsterdam UMC approved the prospective BLR protocol in October 2024. The registry coordination is led by Dr Dorith Claushuis at Amsterdam UMC.
• Associazione Angela Serra for Cancer Research (Modena, Italy)coreStrategic or Co-development PartnerBuilt the RedCap database for the international Burkitt Lymphoma Registry. This technical partnership enables the prospective data collection infrastructure for the global registry.
• AI-REAL (Home – AI-REAL)majorStrategic or Co-development PartnerProvided donation for Burkitt Lymphoma Research in Africa. Professor Dr Anna Schuh and Dr Clara Chamba received the donation on behalf of the network. AI-REAL supports the network's Africa-focused research projects.
• Hospital Clinic de BarcelonacoreStrategic or Co-development PartnerParticipating center for CARTD-BG-01 clinical trial (Dual CART19-BCMA for Burkitt Lymphoma patients). The trial evaluates safety and efficacy of ARI0003 (CART19/269 cells) in patients with relapsed/refractory B-cell aggressive lymphomas.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• European Lymphoma Institute (ELI): European academic consortium coordinating lymphoma clinical trials and research. Directly comparable as a Europe-anchored lymphoma research network with overlapping membership (e.g., Italian, German, French hematologists) and competing trial-coordination scope.
• International Lymphoma Radiation Oncology Group (ILROG): International specialty network focused on radiation oncology for lymphoma. Comparable as a volunteer international consortium with working groups and consensus guidelines, competing for the same KOLs as BLN.
• Mantle Cell Lymphoma Research Consortium: Multi-institution consortium focused on a specific rare lymphoma subtype with biobanking and trial coordination. Comparable structure and mission niche to BLN, though focused on a different lymphoma subtype.
• Lymphoma Research Foundation: US-based nonprofit dedicated to funding lymphoma research and supporting patients. Directly comparable as a disease-specific (lymphoma) nonprofit research funder and convener, though broader than Burkitt Lymphoma alone.
• International Extranodal NK/T-cell Lymphoma Study Group: International research consortium focused on a single rare lymphoma subtype. Closely comparable structure to BLN: small, volunteer-driven, multicenter, working-group-based research coordination for a rare lymphoma.

Broad incumbents

• ECOG-ACRIN Cancer Research Group: Major NCI-sponsored cooperative group running multi-site oncology clinical trials. Comparable as a large-scale clinical trial coordination body, but operates broadly across cancers rather than focusing on Burkitt Lymphoma.
• The Leukemia & Lymphoma Society: Largest US nonprofit funding blood cancer research, including lymphoma subtypes. Comparable as a grantmaking and research-coordination body, but operating at much greater scale and across all blood cancers rather than BL specifically.
• National Cancer Institute (NCI): US federal agency funding and coordinating large-scale cancer research including rare lymphomas. Comparable as a research funder and coordinator that BLN members frequently collaborate with and compete against for grant funding.
• Children's Oncology Group: NIH-funded cooperative pediatric cancer research group running multi-institution clinical trials including pediatric lymphomas. Comparable as a pediatric cancer trial coordination network, overlapping with BLN's Paediatric BL Working Group mission.
• Rare Diseases Clinical Research Network (NIH RDCRN): NIH-funded network of consortia advancing rare disease research through collaborative protocols. Comparable as a federated rare-disease clinical research infrastructure model that BLN's registry approach resembles at smaller scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Burkitt Lymphoma Network